Dimebon belongs to a fast-growing group of "old" drugs that were suggested to be effective for therapy of pathological conditions different from their original targets. Following initial reports of successful Phase II clinical trials for mild-to-moderate Alzheimer's and Huntington's diseases, effects of Dimebon on various neurodegenerative conditions were investigated both in follow-up clinical trials and in various model systems. Although results of Phase III clinical trials carried out so f...Expand abstract
- Publisher copy:
- Copyright date:
Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record